Ulcerative Colitis
Clinical Trial

MAC Clinical Research are currently conducting a trial to test a potential new treatment for ulcerative colitis (UC).

Improving quality of life

Key Information


Receive up to £2,670 plus reasonable travel

Gender and Age

Males and Females aged 18 - 80


Greater Manchester, Lancashire, Merseyside, South Yorkshire, and West Yorkshire

Health Check

Receive a free comprehensive health check

Register Your Interest

Data Privacy Statement
“There are approximately 150,000 people living with Ulcerative Colitis in the UK today, and whilst there are several treatment options available, there is still a real need for additional therapies to stop UC flare-ups. At MAC, we understand that it can have a significant impact on quality of life, and we want to help you navigate life with ulcerative colitis; with your help, we are one step closer to a potential treatment.”
Dr Aliya Asher
Principal Investigator

What Happens Next?

What happens next?

1. Sign Up

Register your interest on our website or over the phone

2. We'll Call You

Our study specialists will call you to discuss your health and check if the trial is suitable for you

3. Eligible?

If eligible, you will be booked in for a 'CHAT' where you'll receive a Patient Information Sheet (PIS)

4. Medical History

If you decide to take part, our medical team will obtain a copy of your medical history from your GP

5. Health Check

You will attend a free comprehensive health check with a MAC doctor and your eligibility will be confirmed

6. Enrollment

You will be enrolled onto the clinical trial and attend scheduled visits (Travel expenses or transport to clinic provided)

About this Ulcerative Colitis Clinical Trial

Ulcerative Colitis (UC) is a chronic inflammatory disease of the rectal & colonic mucosa which is characterised by periods of remission and relapse, or ‘flare-ups’. Autoimmune and inflammatory diseases such as UC can happen when a person’s immune system becomes unbalanced. The study medicine, PT101, has been developed as a variation of a protein in our bodies known as interleukin-2 (IL-2). In previous studies PT101 has been shown to increase a type of immune cell in the body called regulatory T cells (Tregs), which are believed to bring balance back to the immune system and help reduce acute inflammation, a cause of UC flare-ups.

Would you like to keep up to date with clinical research opportunities?